Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells

References

• Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother 2003;4:963–971.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75–85.
   PubMed Web of Science ®Google Scholar
• Radujkovic A, Schad M, Topaly J, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL—inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005;19:1198–1206.
   PubMed Web of Science ®Google Scholar
• Jung JH, Kwon TR, Jeong SJ, et al. Apoptosis induced by tanshinone IIA and cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2 signaling in chronic myeloid leukemia K562 cells. Evid Based Complement Alternat Med 2013;2013:805639.
   PubMed Web of Science ®Google Scholar
• Chen W, Liu L, Luo Y, et al. Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells. Cancer Prev Res (Phila) 2012;5:778–787.
   PubMed Web of Science ®Google Scholar
• Ge Y, Cheng R, Zhou Y, et al. Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E. Mol Cell Biochem 2012;368:17–25.
   PubMed Web of Science ®Google Scholar
• Kong R, Sun B, Jiang H, et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 2012;291:90–98.
   Web of Science ®Google Scholar
• Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 2003; 349:1451–1464.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes JE, O’Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 2004;104:1979–1988.
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Hughes TP, Cortes JE, et al. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma 2013 Nov 12. [Epub head of print]
   Web of Science ®Google Scholar
• Baran Y, Oztekin C, Bassoy EY. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells. Cancer Invest 2010;28:623–628.
   PubMed Web of Science ®Google Scholar
• Parekh H, Liu G, Wei M. A new dawn for the use of traditional Chinese medicine in cancer therapy. Mol Cancer 2009;8:21.
   PubMed Web of Science ®Google Scholar
• Gu Y, Chen T, Meng Z, et al. CaMKII gamma, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine. Blood 2012;120:4829–4839.
   PubMed Web of Science ®Google Scholar
• Lee J, Shen P, Zhang G, et al. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib. Biomed Pharmacother 2012;67: 157–163.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Wohlbold L, van der Kuip H, Miething C, et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 2003;102:2236–2239.
   PubMed Web of Science ®Google Scholar
• Ilic N, Utermark T, Widlund HR, et al. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci USA 2011;108:E699–E708.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345–356.
   PubMed Web of Science ®Google Scholar
• Santos FP, Ravandi F. Advances in treatment of chronic myelogenous leukemia—new treatment options with tyrosine kinase inhibitors. Leuk Lymphoma 2009;50(Suppl. 2):16–26.
   PubMed Web of Science ®Google Scholar
• Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev Anticancer Ther 2008;8:1387–1398.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367:2075–2088.
   PubMed Web of Science ®Google Scholar
• Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 2002;119:3–14.
   PubMed Web of Science ®Google Scholar
• Ghez D, Micol JB, Pasquier F, et al. Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis. Eur J Cancer 2014;49:3666–3670.
   Web of Science ®Google Scholar
• Okabe S, Tauchi T, Tanaka Y, et al. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biol Ther 2014;15:207–215.
   PubMed Web of Science ®Google Scholar
• Kim JH, Jeong SJ, Kwon TR, et al. Cryptotanshinone enhances TNF-alpha-induced apoptosis in chronic myeloid leukemia KBM-5 cells. Apoptosis 2011;16:696–707.
   PubMed Web of Science ®Google Scholar
• Liu P, Xu S, Zhang M, et al. Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide. Metallomics 2013;5:871–878.
   PubMed Web of Science ®Google Scholar